Titre :
  • Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Auteur : Kerklaan, Bojana Milojkovic B.M. ; Diéras, Véronique ; Le Tourneau, Christophe C. ; Mergui-Roelvink, Marja M. ; Huitema, Alwin Dr ; Rosing, Hilde H. ; Beijnen, Jos J.H. ; Marreaud, Sandrine ; Govaerts, Anne-Sophie A.-S. ; Piccart-Gebhart, Martine ; Schellens, Jan J.H.M. ; Awada, Ahmad
Informations sur la publication : Cancer chemotherapy and pharmacology, 71, 1, (page 53-62)
Statut de publication : Publié, 2013-01
Sujet CREF : Cancérologie
Pharmacologie
Toxicologie pharmaceutique
Mots-clés : Activated MAPK pathway
Chemotherapy
Farnesyl transferase inhibitor
Her2-positive breast cancer
Lonafarnib
Paclitaxel
Trastuzumab
Mots-clés MeSH : Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- pharmacokinetics -- therapeutic use
Breast Neoplasms -- drug therapy -- genetics
Dose-Response Relationship, Drug
Female
Humans
Maximum Tolerated Dose
Middle Aged
Paclitaxel -- administration & dosage
Piperidines -- administration & dosage
Pyridines -- administration & dosage
Receptor, ErbB-2 -- genetics
Treatment Outcome
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0344-5704 
info:doi/10.1007/s00280-012-1972-1
info:pmid/23053259